future glp 1 drugs Comparing Ozempic, Wegovy and Other GLP-1 Drugs

In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with obesity, as compared with placebo. Full

Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes - Ophthalmology

GLP1 medicines now address weight loss and other health conditions through innovative formulations and expanded indications, highlighting key questions about their efficacy and safety. https://ja.ma/3JZg8l3

Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds | CNN

In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with